Brennan Aoife 4

4 · Climb Bio, Inc. · Filed Jun 30, 2026

AI-generated summary of this filing

Updated Jun 30, 2026

Climb Bio (CLYM) CEO Brennan Aoife Sells 30,902 Shares

What Happened

Brennan Aoife, President, CEO and Director of Climb Bio (CLYM), had 68,750 restricted stock units (RSUs) convert into 68,750 shares on June 27, 2026. The filing shows those converted shares were net-settled/withheld (reported as a derivative disposition at $0) to cover withholding obligations. On June 29, 2026 she sold 30,902 shares in the open market for a weighted average price of $13.17, generating $406,979 in proceeds.
The RSUs were originally granted June 27, 2024 and vest over four years (25% each year), so the 68,750 shares represent the scheduled annual vesting tranche. The sale was executed under a pre-existing 10b5-1 plan to cover tax withholding tied to the RSU vesting.

Key Details

Transaction dates/prices: RSU conversion 6/27/2026 (68,750 shares); net settlement/withholding reported as disposed at $0; open-market sale 6/29/2026 — 30,902 shares at a weighted avg $13.17 (range $13.02–$13.34), proceeds $406,979.
Shares owned after transaction: not specified in the Form 4.
Notable footnotes: sale was pursuant to a 10b5-1 trading plan adopted Aug 30, 2024 to cover tax withholding; each RSU converts to one share; total holdings reported include an additional 1,751 shares from the company ESPP.
Filing timeliness: Form 4 filed 2026-06-30 for transactions on 6/27 and 6/29 (filing indicates timely reporting).

Context

The June 27 conversion was an RSU settlement (not an option exercise requiring cash); the $0 disposition and the separate open-market sale indicate net settlement/withholding plus a 10b5-1 sale to cover tax obligations — a common routine practice when equity awards vest.
This filing documents routine award vesting and associated tax-related selling, not an independent purchase signal.

Form 4

Period: 2026-06-27

DirectorPresident and CEO

Transactions

Exercise/Conversion
Common Stock
[F1][F2]
2026-06-27+68,750→ 118,633 total
Sale
Common Stock
[F3][F4]
2026-06-29$13.17/sh−30,902$406,979→ 87,731 total
Exercise/Conversion
Restricted Stock Units
[F5][F6]
2026-06-27−68,750→ 137,500 total
→ Common Stock (68,750 underlying)

Footnotes (6)

[F1]Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock
[F2]Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan.
[F3]The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.
[F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
[F5]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
[F6]The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.

Signature

/s/ Chandra Adams, as Attorney-in-Fact|2026-06-30

1 file